Pearls and perils in the management of germ cell tumors.
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
Cancer Survivors
Clinical Trials, Phase III as Topic
Humans
Male
Neoplasms, Germ Cell and Embryonal
/ drug therapy
Organoplatinum Compounds
/ administration & dosage
Palliative Care
Randomized Controlled Trials as Topic
Salvage Therapy
Testicular Neoplasms
/ drug therapy
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 05 2021
01 05 2021
Historique:
pubmed:
13
2
2021
medline:
25
8
2021
entrez:
12
2
2021
Statut:
ppublish
Résumé
Research and innovation over the past half century have rendered testicular cancer a highly curable malignancy. Challenges and uncertainty remain in several aspects related to the management and surveillance of patients with germ cell tumors (GCT). Long-term effects of treatment on survivors of testicular cancer remain as continued areas of interest. This review aims to highlight pearls and perils in the management of patients with GCT. Uncertainty remain regarding complex aspects of first-line and salvage treatments of GCT, interpretation of tumor markers in cases of α-fetoprotein levels less than 25 ng/ml, plateau of β-human chorionic gonadotropin (hCG) levels in patients with initial hCG greater than 50 000 mIU/ml, supportive therapies throughout chemotherapy regimens, and long-term survivorship of patients who underwent surgery or received platinum-based chemotherapy. This review aims to highlight challenges that remain in GCT, review the emerging data in these areas, and provide our institutional opinion on the management in several aspects of GCT. Testicular cancer continues to present challenging clinical scenarios with respect to treatment, surveillance, and long-term management of patients. We review the data and share our institutional knowledge in several challenging areas related to the management of GCT.
Identifiants
pubmed: 33577208
doi: 10.1097/CCO.0000000000000718
pii: 00001622-202105000-00008
doi:
Substances chimiques
Biomarkers, Tumor
0
Organoplatinum Compounds
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
206-211Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA: A Cancer Journal for Clinicians 70:7–30, 2020.
Einhorn LH. Curing metastatic testicular cancer. Proc Nat Acad Sci 2002; 99:4592–4595.
Gilligan T, Lin DW, Aggarwal R, et al. Testicular cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2019; 17:1529–1554.
Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007; 18:917–924.
Cary C, Jacob JM, Albany C, et al. Long-term survival of good-risk germ cell tumor patients after postchemotherapy retroperitoneal lymph node dissection: a comparison of BEP × 3 vs. EP × 4 and treating institution. Clin Genitourin Cancer 2018; 16:e307–e313.
Fein DE, Paulus JK, Mathew P. Reassessment of 4-cycle etoposide and cisplatin as the standard of care for good-risk metastatic germ cell tumors. JAMA Oncol 2018; 4:1661–1662.
Kesler KA, Rieger KM, Hammoud ZT, et al. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg 2008; 85:371–378.
Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003; 97:1869–1875.
Ranganath P, Kesler KA, Einhorn LH. Perioperative morbidity and mortality associated with bleomycin in primary mediastinal nonseminomatous germ cell tumor. J Clin Oncol 2016; 34:4445–4446.
Cathomas R, Klingbiel D, Bernard BD, et al. FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry. J Clin Oncol 2017; 35:4521–4521.
Dieckmann KP, Radtke A, Geczi L, et al. Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J Clin Oncol 2019; 37:1412–1423.
Murray MJ, Halsall DJ, Hook CE, et al. Identification of microRNAs from the miR-371–373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am J Clin Pathol 2011; 135:119–125.
Huddart RA, O’Doherty MJ, Padhani A, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22: the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 2007; 25:3090–3095.
Germà JR, Llanos M, Tabernero JM, Mora J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 1993; 72:2491–2494.
Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. Serum α-fetoprotein in patients with massive hepatic necrosis. Gastroenterology 1977; 72:479–482.
Cassinat B, Guardiola P, Chevret S, et al. Constitutive elevation of serum alpha-fetoprotein in Fanconi anemia. Blood 2000; 96:859–863.
Schefer H, Mattmann S, Joss R. Hereditary persistence of α-fetoprotein: case report and review of the literature. Ann Oncol 1998; 9:667–672.
Albany C, Einhorn L. Pitfalls in management of patients with germ cell tumors and slight elevation of serum α-fetoprotein. J Clin Oncol 2014; 32:2114–2115.
Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998; 16:1294–1297.
Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993; 11:324–329.
Kondagunta G, Bacik J, Donadio A. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005; 23:6549–6555.
Loehrer P, Gonin R, Nichols C. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16:2500–2504.
Loehrer PJ Sr, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109:540–546.
Einhorn L, Williams S, Chamness A. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007; 357:340–348.
Feldman D, Sheinfeld J, Bajorin D. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol 2010; 28:1706–1713.
Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol 1995; 13:1170–1176.
Sharp DS, Carver BS, Eggener SE, et al. Clinical outcome and predictors of survival in late relapse of germ cell tumor. J Clin Oncol 2008; 26:5524–5529.
Gault DT. Extravasation injuries. Br J Plast Surg 1993; 46:91–96.
Stanford BL, Hardwicke F. A review of clinical experience with paclitaxel extravasations. Support Care Cancer 2003; 11:270–277.
Albany C, Brames MJ, Fausel C, et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012; 30:3998–4003.
Ikeda A, Kawai K, Ando S, et al. Management of ureteral obstruction in advanced testicular tumor with lymph node metastasis. Japn J Clin Oncol 2012; 42:748–752.
Khanal N, Ahmed S, Kalra M, et al. The effects of hypogonadism on quality of life in survivors of germ cell tumors treated with surgery alone versus surgery plus platinum-based chemotherapy. Support Care Cancer 2019; 28:3165–3170.
Zaid MA, Gathirua-Mwangi WG, Fung C, et al. Clinical and genetic risk factors for adverse metabolic outcomes in North American testicular cancer survivors. J Nat Compr Cancer Netw 2018; 16:257–265.